Equities analysts forecast that Moderna, Inc. (NASDAQ:MRNA – Get Rating) will announce sales of $4.50 billion for the current fiscal quarter, according to Zacks. Seven analysts have made estimates for Moderna’s earnings. The highest sales estimate is $5.49 billion and the lowest is $3.02 billion. Moderna reported sales of $1.94 billion during the same quarter last year, which suggests a positive year over year growth rate of 132%. The company is expected to announce its next earnings results before the market opens on Monday, January 1st.
According to Zacks, analysts expect that Moderna will report full year sales of $22.14 billion for the current fiscal year, with estimates ranging from $19.57 billion to $25.86 billion. For the next fiscal year, analysts forecast that the business will report sales of $10.74 billion, with estimates ranging from $3.99 billion to $17.02 billion. Zacks’ sales calculations are an average based on a survey of research analysts that cover Moderna.
Moderna (NASDAQ:MRNA – Get Rating) last posted its earnings results on Thursday, February 24th. The company reported $11.29 earnings per share for the quarter, topping analysts’ consensus estimates of $9.83 by $1.46. The firm had revenue of $7.21 billion for the quarter, compared to analysts’ expectations of $6.73 billion. Moderna had a net margin of 66.06% and a return on equity of 140.21%. The company’s revenue was up 1163.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.69) earnings per share.
In other Moderna news, CEO Stephane Bancel sold 9,000 shares of the company’s stock in a transaction dated Wednesday, April 27th. The shares were sold at an average price of $142.14, for a total value of $1,279,260.00. Following the completion of the sale, the chief executive officer now directly owns 5,421,535 shares of the company’s stock, valued at approximately $770,616,984.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Stephen Hoge sold 20,000 shares of the company’s stock in a transaction dated Monday, February 14th. The stock was sold at an average price of $157.71, for a total transaction of $3,154,200.00. The disclosure for this sale can be found here. Insiders sold a total of 208,054 shares of company stock worth $33,524,074 in the last 90 days. 17.30% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the company. Field & Main Bank bought a new position in shares of Moderna during the 4th quarter valued at approximately $25,000. Confluence Wealth Services Inc. bought a new position in Moderna in the 4th quarter worth approximately $25,000. Standard Family Office LLC bought a new position in Moderna in the 4th quarter worth approximately $25,000. Reilly Financial Advisors LLC bought a new position in Moderna in the 4th quarter worth approximately $26,000. Finally, Gradient Investments LLC boosted its holdings in Moderna by 2,000.0% in the 4th quarter. Gradient Investments LLC now owns 105 shares of the company’s stock worth $27,000 after buying an additional 100 shares during the period. 60.11% of the stock is owned by hedge funds and other institutional investors.
Shares of Moderna stock traded down $8.11 during trading on Friday, hitting $134.41. The company’s stock had a trading volume of 7,095,551 shares, compared to its average volume of 5,121,028. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.76 and a quick ratio of 1.60. Moderna has a 52 week low of $122.01 and a 52 week high of $497.49. The stock has a market cap of $54.17 billion, a price-to-earnings ratio of 4.75, a price-to-earnings-growth ratio of 0.81 and a beta of 1.55. The stock has a 50-day moving average price of $156.76 and a two-hundred day moving average price of $214.08.
About Moderna (Get Rating)
Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics.
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.